Can a 30‑year‑old woman with diabetes diagnosed at age 28, BMI 29 kg/m², Hashimoto thyroiditis, a mother with Hashimoto thyroiditis, and a father with diabetes have latent autoimmune diabetes in adults (LADA) or maturity‑onset diabetes of the young (MODY)?

Can This Patient Have LADA or MODY?

Yes, this patient could have LADA (latent autoimmune diabetes in adults), and this diagnosis should be strongly considered given her age at onset, personal history of Hashimoto thyroiditis, and family history of autoimmune disease. MODY is less likely but cannot be completely excluded without genetic testing.

LADA is the Primary Consideration

Clinical Features Supporting LADA

This patient's presentation aligns well with LADA based on several key factors:

• Age at onset (28 years): LADA typically presents after age 30, but onset in the late 20s is well within the spectrum of adult-onset autoimmune diabetes 1, 2.

• Hashimoto thyroiditis: The presence of thyroid autoimmunity is a strong indicator of LADA. Studies show that 16.7-18.9% of LADA patients have thyroid autoimmunity, significantly higher than type 2 diabetes (7%) 3, 4. LADA patients with high-titer GAD antibodies have a 50% prevalence of thyroid autoimmunity 4.

• Maternal history of Hashimoto: Family history of autoimmune disease supports the AABBCC diagnostic approach, where personal or family history of autoimmune disease or polyglandular autoimmune syndromes points toward autoimmune diabetes 5.

• BMI of 29 kg/m²: While this is above the typical BMI <25 kg/m² threshold often associated with type 1 diabetes, LADA is characterized by phenotypic heterogeneity and can present with higher BMI due to concurrent insulin resistance 2. The 2025 ADA guidelines acknowledge that individuals can have features of both type 1 and type 2 diabetes 5.

Diagnostic Testing Required

To confirm LADA, measure GAD antibodies (GADA) and fasting C-peptide levels 5, 6:

• GAD antibody positivity defines LADA in adults with diabetes onset after age 25-30 who don't require insulin for at least 6 months 3, 6.

• C-peptide levels help assess β-cell function. In LADA with thyroid autoimmunity, C-peptide levels are typically lower (mean 0.69 ng/mL) compared to those without thyroid autoimmunity (1.9 ng/mL) 3. C-peptide values of 200-600 pmol/L (0.6-1.8 ng/mL) are consistent with type 1 diabetes or MODY 5.

• Additional autoantibodies to consider include insulin autoantibodies (IAA) and islet antigen 2 (IA-2) antibodies 5.

Clinical Implications if LADA is Confirmed

If this patient has LADA with thyroid autoimmunity, expect:

• More rapid progression to insulin dependence: Patients with thyroid autoimmunity progress to insulin treatment faster (3.2 years vs 4.98 years) 3.

• Poorer glycemic control: Higher HbA1c levels (9.8% vs 9.1%) are seen in LADA patients with thyroid autoimmunity 3.

• Higher insulin requirements: More frequent need for basal-bolus insulin regimens (56.7% vs 35.1%) 3.

• Risk of thyroid dysfunction: 47.1% of LADA patients with thyroid antibodies develop thyroid dysfunction 4.

MODY is Less Likely But Should Be Considered

Features Against MODY

• Late age of onset (28 years): MODY typically presents before age 25, often in adolescence or early adulthood 5.

• BMI of 29 kg/m²: MODY patients typically have normal or low BMI 5.

• Presence of Hashimoto thyroiditis: This autoimmune condition is not characteristic of MODY, which is a non-autoimmune monogenic disorder.

When to Test for MODY

Consider genetic testing for MODY if 5:

• GAD antibodies are negative
• C-peptide levels are preserved (200-600 pmol/L or 0.6-1.8 ng/mL)
• Strong family history of diabetes in multiple generations (father with diabetes could suggest this, but one generation is insufficient)
• Absence of features of metabolic syndrome beyond the elevated BMI

Important Caveat

The 2025 ADA guidelines note that misdiagnosis is common, occurring in 40% of adults with new type 1 diabetes who are initially labeled as type 2 diabetes 5. Given this patient's autoimmune background, testing for LADA should be the first priority before considering MODY.

Recommended Diagnostic Algorithm

1. Measure GAD antibodies immediately 5, 6
2. Measure fasting C-peptide (ensure not within 2 weeks of any hyperglycemic emergency and before any insulin treatment) 5
3. Check thyroid function and TPO/TG antibodies if not recently done 3, 4
4. If GAD-positive: Diagnose as LADA and plan for earlier insulin initiation given thyroid autoimmunity 3
5. If GAD-negative with preserved C-peptide: Consider genetic testing for MODY, though this remains less likely given the clinical picture 5